

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

1. (Currently Amended) An isolated polypeptide selected from the group consisting of:
  - a) a polypeptide comprising an amino acid sequence ~~selected from the group consisting of SEQ ID NO:1-6, of SEQ ID NO:1, and~~
  - b) a naturally occurring polypeptide comprising an amino acid sequence having at least 90% identical about 95% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-6, of SEQ ID NO:1, wherein the polypeptide has cysteinyl leukotriene receptor activity.
  - c) ~~a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-6, and~~
  - d) ~~an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-6.~~
2. (Currently Amended) ~~An~~ The isolated polypeptide of claim 1 ~~selected from the group consisting of SEQ ID NO:1-6 comprising an amino acid sequence of SEQ ID NO:1.~~
3. (Currently Amended) An isolated polynucleotide encoding a polypeptide ~~of claim 1~~ selected from the group consisting of:
  - a) a polypeptide comprising an amino acid sequence of SEQ ID NO:1;  
and
  - b) a polypeptide comprising an amino acid sequence having at least about 95% sequence identity to an amino acid sequence of SEQ ID NO:1, wherein the polypeptide has cysteinyl leukotriene receptor activity.
4. (Currently Amended) ~~An~~ The isolated polynucleotide of claim 3 encoding a polypeptide ~~of claim 2~~ comprising an amino acid sequence of SEQ ID NO:1.

5. (Currently Amended) ~~An~~ The isolated polynucleotide of claim 4 ~~selected from the group consisting of SEQ ID NO:7-12~~ comprising a polynucleotide sequence of SEQ ID NO:7.

6. (Currently Amended) A recombinant polynucleotide comprising a promoter sequence operably linked to a the polynucleotide of claim 3.

7. (Currently Amended) A ~~An~~ isolated cell transformed with a the recombinant polynucleotide of claim 6.

8. (Cancelled).

9. (Currently Amended) A method for producing a the polypeptide of claim 1, the method comprising:

a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 1, and

b) recovering the polypeptide so expressed.

10. (Cancelled).

11. (Currently Amended) An isolated polynucleotide selected from the group consisting of:

a) a polynucleotide comprising a polynucleotide sequence ~~selected from the group consisting of SEQ ID NO:7-12 of SEQ ID NO:7,~~

b) a ~~naturally occurring~~ polynucleotide comprising a polynucleotide sequence having at least 90% identical about 95% sequence identity to a polynucleotide sequence ~~selected from the group consisting of SEQ ID NO:7-12 of SEQ ID NO:7, wherein the polynucleotide encodes a polypeptide that has cysteinyl leukotriene receptor activity,~~

c) a polynucleotide complementary to the polynucleotide of a),

d) a polynucleotide complementary to the polynucleotide of b), and

e) an RNA equivalent of a)-d).

12.-15. (Cancelled).

16. (Currently Amended) A composition comprising a the polypeptide of claim 1 and a pharmaceutically acceptable excipient.

17. (Currently Amended) A The composition of claim 16, wherein the polypeptide has an amino acid sequence ~~selected from the group consisting of SEQ ID NO:1-6 of SEQ ID NO:1.~~

18. (Cancelled).

19. (Currently Amended) A method for screening a compound for effectiveness as an agonist of a the polypeptide of claim 1, the method comprising:

a) exposing a sample comprising a the polypeptide of claim 1 to a compound, and

b) detecting agonist activity in the sample.

20.-21. (Cancelled).

22. (Currently Amended) A method for screening a compound for effectiveness as an antagonist of a the polypeptide of claim 1, the method comprising:

- a) exposing a sample comprising a the polypeptide of claim 1 to a compound, and
- b) detecting antagonist activity in the sample.

23.-25. (Cancelled).

26. (Original) A method of screening for a compound that modulates the activity of the polypeptide of claim 1, said method comprising:

- a) combining the polypeptide of claim 1 with at least one test compound under conditions permissive for the activity of the polypeptide of claim 1,
- b) assessing the activity of the polypeptide of claim 1 in the presence of the test compound, and
- c) comparing the activity of the polypeptide of claim 1 in the presence of the test compound with the activity of the polypeptide of claim 1 in the absence of the test compound, wherein a change in the activity of the polypeptide of claim 1 in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide of claim 1.

27.-56. (Cancelled).

57. (New) The isolated polypeptide of claim 1 comprising an amino acid sequence having at least about 96% sequence identity to an amino acid sequence of SEQ ID NO:1, wherein the polypeptide has cysteinyl leukotriene receptor activity.

58. (New) The isolated polypeptide of claim 1 comprising an amino acid sequence having at least about 97% sequence identity to an amino acid sequence of SEQ ID NO:1, wherein the polypeptide has cysteinyl leukotriene receptor activity.

59. (New) The isolated polypeptide of claim 1 comprising an amino acid sequence having at least about 98% sequence identity to an amino acid sequence of SEQ ID NO:1, wherein the polypeptide has cysteinyl leukotriene receptor activity.

60. (New) The isolated polypeptide of claim 1 comprising an amino acid sequence having at least about 99% sequence identity to an amino acid sequence of SEQ ID NO:1, wherein the polypeptide has cysteinyl leukotriene receptor activity.

61. (New) The isolated polypeptide of claim 1, wherein the polypeptide is a human polypeptide.